SCHEMBL25856856

SCHEMBL25856856

CCC1(CC)CC(=O)c2cc(-c3cc(-c4ccccc4C)no3)ccc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ATM Q13315 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ NFKB2 Q00653 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ RELA Q04206 1/20 0.43
▸ MAOB P27338 4/20 0.41
▸ CNR1 P21554 1/20 0.41
▸ CNR2 P34972 1/20 0.41
▸ CASP3 P42574 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25856949 0.90 CNR1 (0.41) NPC1RAB9ACYP1A2SMN1; SMN2MAPT
SCHEMBL25856895 0.89 RAB9A (0.42) NPC1RAB9ACYP1A2SMN1; SMN2ATM
SCHEMBL23558461 0.89 NPC1 (0.45) NPC1RAB9ACYP1A2SMN1; SMN2MEN1
SCHEMBL25856900 0.85 MAOB (0.43) NPC1RAB9AATMMEN1MAPT
SCHEMBL23558330 0.84 RAB9A (0.40) NPC1RAB9ACYP1A2SMN1; SMN2ATM
SCHEMBL23523958 0.82 NR1H4 (0.50) NPC1RAB9ACYP1A2SMN1; SMN2MEN1
SCHEMBL30355837 0.82 NR1H4 (0.50) NPC1RAB9ACYP1A2SMN1; SMN2MEN1
SCHEMBL25856896 0.82 MAPT (0.45) NPC1RAB9ACYP1A2SMN1; SMN2MEN1
SCHEMBL25856668 0.81 CNR1 (0.40) SMN1; SMN2ATMMAPTHPGDKMT2A
SCHEMBL23558238 0.81 ALDH1A1 (0.45) NPC1RAB9ACYP1A2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 NPC1 301/4885RAB9A 3056/4885CYP1A2 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback